UCLA Department of Bioengineering

Industrial Impact

ThinkCyte Inc. | July 12, 2022

ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced that applications of its Ghost Cytometry technology were presented at several leading industry meetings. In May, the company was selected to present applications of the platform to experts in drug discovery at the prestigious Keystone Symposia. The company was also selected to deliver a podium presentation at the 2022 International Association for the Advancement of Cytometry's annual me...

Industrial Impact

Cyclica Inc. | February 10, 2022

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...

Cell and Gene Therapy

PRNewswire | June 12, 2023

BioCentriq®, a strategic CDMO specializing in cell therapy announced that it has expanded its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). The partnership was originally announced in March of 2021. In the initial phase of the collaboration, the Kytopen and BioCentriq teams worked together to test transfection of T-cells using Kytopen's Flowfect® technology and the potential impact to both autologous and ...

Industrial Impact

Enveric Biosciences, Inc | July 14, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy Psy...